bioAffinity Technologies, Inc. (the “Company”) filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission on September 11, 2026. The filing was made to disclose that the Company has prepared presentation materials intended for use during upcoming investor events.
According to the filing, the presentation materials are designed to provide information about the Company’s operations and performance. Management intends to utilize these materials during the H.C. Wainwright 28th Annual Global Investment Conference.
The conference is scheduled to take place from September 14, 2026, through September 16, 2026. The Company furnished the presentation materials as Exhibit 99.1 to this report.
The filing includes standard regulatory language indicating that the information provided in Item 7.01 and the accompanying exhibit is furnished and shall not be deemed to be “filed” for the purposes of the Securities Exchange Act of 1934.
